Kester Thomas J 4
4 · InspireMD, Inc. · Filed May 16, 2023
Insider Transaction Report
Form 4
InspireMD, Inc.NSPR
Kester Thomas J
Director
Transactions
- Purchase
Common Stock
2023-05-12$1.63/sh+61,249$100,001→ 108,590 total - Purchase
Series I Warrants to purchase Common Stock
2023-05-12$1.63/sh+30,624$50,000→ 30,624 totalExercise: $1.38From: 2023-05-15→ Common Stock (30,624 underlying) - Purchase
Series H Warrants to purchase Common Stock
2023-05-12$1.63/sh+30,625$50,001→ 30,625 totalExercise: $1.38From: 2023-05-15→ Common Stock (30,625 underlying) - Purchase
Series J Warrants to purchase Common Stock
2023-05-12$1.63/sh+30,625$50,001→ 30,625 totalExercise: $1.38From: 2023-05-15→ Common Stock (30,625 underlying) - Purchase
Series K Warrants to purchase Common Stock
2023-05-12$1.63/sh+30,624$50,000→ 30,624 totalExercise: $1.38From: 2023-05-15→ Common Stock (30,624 underlying)
Footnotes (10)
- [F1]The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").
- [F10]The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.
- [F2]The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.
- [F3]The aggregate number of warrants reported in this row consists of 30,625 Series H Warrants that were acquired in the Private Placement.
- [F4]The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.
- [F5]The aggregate number of warrants reported in this row consists of 30,624 Series I Warrants that were acquired in the Private Placement.
- [F6]The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).
- [F7]The aggregate number of warrants reported in this row consists of 30,625 Series J Warrants that were acquired in the Private Placement.
- [F8]The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.
- [F9]The aggregate number of warrants reported in this row consists of 30,624 Series K Warrants that were acquired in the Private Placement.